The Convergence of Science and Hope

Argos Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. The Company has developed a pipeline of products based on its proprietary Arcelis technology platform.

View the Arcelis Platform

hp_adapt_its_personal

Argos in The News

804758804480804027fd539e46-a93e-4135-8451-389b13848f49579711c5-13b8-4c50-9b2d-2f2a67330e1e86d42f2b-1bdf-4002-8db3-ef006efa0da6ARGS_News_2015_1_23_General_Releases.pdfARGS_News_2015_1_22_General_Releases.pdfARGS_News_2015_1_20_General_Releases.pdf1752419186177341232015-1-23T11:0:0-5:02015-1-22T8:30:0-5:02015-1-20T8:30:0-5:0892671892460892000General ReleasesGeneral ReleasesGeneral ReleasesDr. Fred Miesowicz Will Present a Case Study Review of Logistics of Cell Therapy Manufacturing on January 26th and Will Participate in a Breakfast Briefing on January 27thDr. Mark DeBenedette Will Discuss the Use of Multi-Color Flow Cytometry to Monitor T-Cell Responses During the 7th Immunotherapeutics and Immunomonitoring Conference on January 29th in San DiegoDr. Charles Nicolette Will Discuss Immunotherapy for Cancer Treatment on January 27thArgos Therapeutics Chief Operating Officer to Speak at Phacilitate Cell & Gene Therapy Forum 2015Argos Therapeutics Director of Immunology to Speak at the GTCbio Novel Immunotherapeutics Summit 2015Argos Therapeutics Chief Scientific Officer to Speak at the Personalized Medicine World Conference 2015818181201520152015No Error0

Argos Therapeutics Chief Operating Officer to Speak at Phacilitate Cell & Gene Therapy Forum 2015
Read more

Argos Therapeutics Director of Immunology to Speak at the GTCbio Novel Immunotherapeutics Summit 2015
Read more

Argos Therapeutics Chief Scientific Officer to Speak at the Personalized Medicine World Conference 2015
Read more

> More News & Events Here.

1999

When Our Company Was Founded

2006

First Arcelis product (AGS-003) clinical trial initiated in mRCC

2013

Phase 3 mRCC ADAPT Study Launched

180

Newly diagnosed RCC patients daily in the US, of which ~ 30 will present with stage IV or metastatic RCC